Dipeptidyl peptidase-4 (DPP-4) inhibitors prior authorization
Customize your policy alerts
Sign up for allcareadvantage Policy 024.2 alerts
Get alerted when Policy 024.2 changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization coverage rules for non-preferred and non-formulary dipeptidyl peptidase-4 (DPP-4) inhibitors for members with type 2 diabetes mellitus, including combination agents containing metformin and DPP-4 inhibitors.
No material clinical or coverage changes in this revision.
Coverage Criteria
Initial Authorization
Covered when ALL of the following are met
Approval length up to 1 year; preserve branch logic for preferred vs non-preferred vs non-formulary.
Renewal Authorization
Covered when ALL of the following are met
Approve up to 1 year when criteria are met; otherwise deny.
Coverage for dipeptidyl peptidase‑4 (DPP‑4) inhibitors is limited to members with a documented diagnosis of type 2 diabetes mellitus. If documentation does not support a diagnosis of type 2 diabetes mellitus, the request must be denied.
Initial Therapy Requirements
Initial therapy criteria
Initial therapy requirements
Approval up to 1 year.
Renewal / Continuation Criteria
Renewal criteria
Renewal requires:
Approve up to 1 year when met; otherwise deny.
Provider Actions and Documentation Requirements
Prior authorization required; approvals up to 1 year
Prior authorization is required for non-preferred and non-formulary DPP-4 (DPP‑IV) inhibitors. When all coverage criteria are met, approvals are granted for up to 1 year.
Step requirement: metformin (and preferred agents as applicable)
Members must have tried and failed, or have a documented contraindication to, first-line treatment with metformin before non-preferred formulary DPP-4 agents are approved. Additionally, failure/contraindication to a preferred formulary DPP-4 inhibitor is required before approving non-formulary agents (unless a clinical rationale is submitted).
Required clinical documentation and rationale
Documentation must clearly show a diagnosis of type 2 diabetes mellitus and evidence of prior trials and failures or documented contraindications to metformin and to preferred formulary DPP-4 agents as applicable. For requests for non-preferred or non-formulary agents, a clinical rationale supporting use over preferred/formulary agents must be submitted; renewals require recent chart notes supporting continued use.
- Diagnosis of type 2 diabetes mellitus documented in the record
- Evidence of trial and failure or contraindication to metformin (first-line)
- Evidence of trial and failure or contraindication to preferred formulary DPP-4 agent(s) when required
- Clinical rationale submitted for use of non-preferred or non-formulary agent over formulary options
- Recent chart notes supporting continued use for renewals
Denial risks for insufficient diagnosis or prior therapy
Requests will be denied if documentation does not support a diagnosis of type 2 diabetes mellitus or fails to demonstrate required prior trials/failures or contraindications to metformin and applicable formulary DPP-4 agents; lacking a submitted clinical rationale for non-preferred or non-formulary use also risks denial.
- Deny if no documentation of type 2 diabetes mellitus
- Deny if no evidence of trial/failure or contraindication to metformin when required
- Deny if provider does not submit rationale to support non-preferred/non-formulary use over formulary agents
Renewal denial conditions
For renewals, denials will occur if the member did not meet the initial prior authorization criteria or if recent chart notes do not support continuation of the medication; approvals on renewal are up to 1 year when continuation is supported.
- Renewal denied if initial PA criteria were not met
- Renewal denied if recent chart notes do not support continued therapy
- If renewal criteria met, approve up to 1 year
Step Therapy Requirements
| Step | Required prior therapy / condition | Next authorized agent | Coverage status |
|---|---|---|---|
| {"text":"1","status":""}|{"text":"Documentation supports diagnosis of type 2 diabetes mellitus","status":""}|{"text":"Proceed to trial of metformin","status":""}|{"text":"","status":""} | |||
| {"text":"2","status":""}|{"text":"Trial and failure of, or contraindication to, first‑line metformin","status":""}|{"text":"Trial of preferred formulary DPP‑4 inhibitor (or approval if contraindication)","status":""}|{"text":"","status":""} | |||
| {"text":"3","status":""}|{"text":"Trial and failure of, or contraindication to, preferred formulary DPP‑4 inhibitor OR provider submits clinical rationale supporting non‑preferred agent over preferred","status":""}|{"text":"Non‑preferred formulary DPP‑4 agent — approve up to 1 year when criteria met","status":"covered"} | |||
| {"text":"4","status":""}|{"text":"Trial and failure of, or contraindication to, both preferred and non‑preferred formulary agents OR provider submits clinical rationale supporting non‑formulary agent over all formulary agents","status":""}|{"text":"Non‑formulary DPP‑4 agent — approve up to 1 year when criteria met","status":"covered"} |
Definitions
Background
Dipeptidyl peptidase‑4 (DPP‑4) inhibitors are an oral antihyperglycemic drug class used for glycemic control in patients with type 2 diabetes mellitus. This policy defines prior authorization requirements for non‑preferred and non‑formulary DPP‑4 agents (including combination products containing metformin), emphasizing use after first‑line therapy with metformin and, when applicable, preferred formulary DPP‑4 agents have failed or are contraindicated.
Prior authorization is required for non‑preferred and non‑formulary DPP‑4 inhibitors; when criteria are met, approvals may be granted for up to 1 year. Documentation submitted must demonstrate the diagnosis and relevant prior trials, failures, or contraindications, and for non‑preferred or non‑formulary agents must include a clinical rationale when required by the criteria.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.